EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Less Restrictive Medicaid Policies for Direct‐Acting Antiviral Access Are Associated With Greater Declines in Hepatocellular Carcinoma Deaths

Gabriel V Lupu iD, Bhagyashree Behera, A Sidney Barritt, Sasha Deutsch-Link iD, Jane Giang, Ellen W Green iD, Oren K Fix, Neil D Shah, Hersh Shroff, Andrew M Moon iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.71624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Gabriel V Lupu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, The University of North Carolina, Chapel hill, North Carolina, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Medicaid, Antiviral Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the United States (US), chronic hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC). Direct‐acting antivirals (DAAs) cure HCV and reduce HCC risk, but Medicaid DAA coverage varies across states.

Aim

We assessed whether Medicaid DAA access was associated with trends in HCC‐related deaths.

Methods

We analyzed CDC WONDER death certificate data (1999–2023) to assess HCC‐related mortality. US states were grouped based on Medicaid DAA prior authorization restrictions using the Hepatitis C: State of Medicaid Access scoring system: A+/A ( n = 28), B ( n = 11), and C/D ( n = 12). We used NCI Joinpoint software to calculate the annual percentage change (APC) and average annual percent change (AAPC) in age‐adjusted death rate. State‐specific HCC crude death rates were analyzed before and after 2014, alongside changes in Medicaid DAA policies from 2014 to 2024.

Results

Before 2017, HCC‐related death rates were positive in group A + /A (APC 2.01, 1999–2017), group B (APC 3.40, 1999–2009), and group C/D (APC 2.04, 1999–2023). Age‐adjusted death rates became negative in group A+/A states (APC −0.19, 2017–2023), while death rates continued to be positive for group B states (APC 1.49, 2009–2023) and group C/D states (APC 2.04, 2017–2023). The AAPC (1999–2023) was lowest in group A + /A (1.46), followed by group B (2.28) and C/D (2.04). From 2014 to 2024 accessibility to DAAs improved.

Conclusion

Increased DAA access was associated with reduced HCC‐related death rates. Improved HCV treatment could contribute to decreased HCC incidence and recurrence, enhance linkage to subspecialty care, and prevent liver‐related decompensation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMedicaidAntiviral AgentsHepatitis C, ChronicHealth Services AccessibilityHumansUnited StatesFemaleMaleMiddle Aged

Stichwörter der Autor:innen

epidemiologyhepatitis Chepatocellular carcinomalivermedicaidoutcomes research

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, The University of North Carolina, Chapel hill, North Carolina, USA.
  • Department of Pharmacy, The University of North Carolina Health, Chapel hill, North Carolina, USA.
  • Lineberger Cancer Center, The University of North Carolina, Chapel hill, North Carolina, USA.

ORCID-Profile: Gabriel V Lupu, Sasha Deutsch-Link, Ellen W Green, Andrew M Moon

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Lupu, G. V., Behera, B., Barritt, A. S., Deutsch-Link, S., Giang, J., Green, E. W., Fix, O. K., Shah, N. D., Shroff, H., & Moon, A. M. (2026). Less Restrictive Medicaid Policies for Direct‐Acting Antiviral Access Are Associated With Greater Declines in Hepatocellular Carcinoma Deaths. Cancer Medicine. https://doi.org/10.1002/cam4.71624

Vancouver

Lupu GV, Behera B, Barritt AS, Deutsch-Link S, Giang J, Green EW, et al. Less Restrictive Medicaid Policies for Direct‐Acting Antiviral Access Are Associated With Greater Declines in Hepatocellular Carcinoma Deaths. Cancer Medicine. 2026. doi:10.1002/cam4.71624

BibTeX
@article{Lupu2026,
  author = {Lupu, Gabriel V and Behera, Bhagyashree and Barritt, A Sidney and Deutsch-Link, Sasha and Giang, Jane and Green, Ellen W and Fix, Oren K and Shah, Neil D and Shroff, Hersh and Moon, Andrew M},
  title = {Less Restrictive Medicaid Policies for Direct‐Acting Antiviral Access Are Associated With Greater Declines in Hepatocellular Carcinoma Deaths},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71624}
}
Kostenlos starten →